MRMara Răzniceanu

Mara Răzniceanu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mara Răzniceanu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Timing Matters: Two Divergent Paths in the Multimodal Treatment of Merkel Cell Carcinoma

    by Mara Răzniceanu, Monica Buzemurgă

    Merkel cell carcinoma (MCC) is a rare but aggressive cutaneous neuroendocrine malignancy with high rates of recurrence and metastasis. Optimal management requires a multidisciplinary approach, including surgery, radiotherapy, and, increasingly, immunotherapy with checkpoint inhibitors. We present a comparative report of two male patients with axillary nodal involvement from MCC who underwent multimodal treatment. The first patient, a 73-year-old male with known primary cutaneous MCC of the forearm, underwent surgical lymphadenectomy followed by postoperative radiotherapy and immunotherapy with Avelumab between February and September 2021, achieving stable disease without progression. The second patient, a 66-year-old male with nodal MCC of unknown primary origin, initially progressed on cisplatin-etoposide chemotherapy. However, early initiation of Avelumab combined with preoperative radiotherapy, followed by surgical lymphadenectomy, resulted in significant tumor regression and a complete pathological response. These cases underscore the crucial importance of integrating early systemic immunotherapy, meticulous radiotherapy planning, and personalized sequencing of multimodal therapies to optimize disease control. The contrasting outcomes emphasize the need for flexible, patient-tailored strategies in the management of Merkel cell carcinoma, particularly in the era of immunotherapy.

  • Open Access

    Predictive Risk Factors for Low Anterior Resection Syndrome (LARS) in Rectal Cancer—An Observational Cohort Study

    by Sorinel Lunca, Stefan Morarasu, Constantin Osman, Fadi Al Shatarat, Tudor Gramada, Mara Razniceanu, Monica Buzemurga, Emanuel Baltig, Raluca Zaharia, Wee Liam Ong, et al.

    Background/Objectives: The improved long-term survival of rectal cancer patients has led to a major increase in the prevalence of functional complications. Understanding which patients are prone to develop major LARS is important for their preoperative counselling and follow-up. Herein, we aimed to assess the risk factors for LARS. Methods: This is a retrospective cohort study on rectal cancer patients. All patient and tumour variables, management plan, type of neoadjuvant therapy, radiation dose to anal sphincter, and perioperative outcomes were collected from the hospital electronic databases. We quantified LARS and compared the score before and after surgery (mean follow-up of 42.2 ± 32 months). Results: A total of 182 patients were included for the final analysis. LARS was present in 43.4% (n = 79) of patients, with 14.8% (n = 27) having minor LARS and 28.5% (n = 52) having major LARS. Age (p = 0.03), male gender (p < 0.00001), smoking (p = 0.04), neoadjuvant radiotherapy (p = 0.02), rectal stump length (p = 0.008), end-to-end anastomosis (p = 0.008), and ileostomy (p = 0.002) were found to significantly increase the rate of LARS. A logistic regression model based on the above variables was able to predict major LARS with good predictive value (AUC 0.700). Conclusions: LARS is highly common after sphincter-preserving surgery, and it is significantly more common in young, male patients with a history of smoking, having mid-lower rectal cancers with neoadjuvant radiotherapy, and undergoing TME surgery with end-to-end low anastomosis and ileostomy.


  • Open Access

    Synchronous Esophageal Squamous Cell Carcinoma And Oropharyngeal Carcinoma: Diagnosis And Management In A 45-Year-Old Patient

    by Mara Răzniceanu, Ioana-Maria Calancea, Monica Buzemurgă

    The occurrence of multiple primary cancers in patients is common. Esophageal squamous cell carcinoma (ESCC) may be associated with a second head and neck primary malignancy (HNSPM), which worsens prognosis. We describe here the case of a 54-year-old male with ESCC presenting as a tumor in the middle third of the thoracic esophagus, accompanied by progressive dysphagia and significant weight loss. A subsequent PET-CT revealed an oropharingeal mass that was confirmed by videofibroscopy and biopsy as a base of the tongue squamous cell carcinoma (SCC). Staging for both tumors after complete evaluation was as following: oropharyngeal tumor cT3N3bM0 and esophageal tumor cT4aN0M0. Treatment included neoadjuvant chemoradiotherapy with Carboplatin and Paclitaxel, in combination with 54 Gy radiotherapy targeting the esophageal tumor. Post-treatment imaging demonstrated regression of the esophageal tumor, but there was no clinical or imaging response of the oropharyngeal tumor. Definitive radiotherapy with concurrent Cetuximab was initiated for the oropharyngeal SCC, but due to skin toxicity (grade 3 radioepithelitis), the treatment needed interruption for a week. Follow-up CT imaging revealed a favorable response of the oropharyngeal tumor. Prospective studies are needed to identify the optimal treatment for synchronous cancers, and the multidisciplinary team (MDT) plays an important role to decide the adapted approach for these patients.